Return on Capital (ROC)
Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Return on Invested Capital (ROIC)
Allergan PLC, ROIC calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | (5,356,995) | (5,673,614) | (10,550,503) | (2,001,620) | (3,502,617) | |
| Invested capital2 | 80,268,300) | 91,098,773) | 103,552,681) | 111,246,522) | 127,501,981) | |
| Performance Ratio | ||||||
| ROIC3 | -6.67% | -6.23% | -10.19% | -1.80% | -2.75% | |
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| AbbVie Inc. | 14.74% | — | — | — | — | |
| Amgen Inc. | 22.74% | — | — | — | — | |
| Bristol-Myers Squibb Co. | 3.06% | — | — | — | — | |
| Danaher Corp. | 3.57% | — | — | — | — | |
| Eli Lilly & Co. | 22.93% | — | — | — | — | |
| Gilead Sciences Inc. | 12.92% | — | — | — | — | |
| Johnson & Johnson | 12.94% | — | — | — | — | |
| Merck & Co. Inc. | 18.52% | — | — | — | — | |
| Pfizer Inc. | 14.19% | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 34.05% | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 6.69% | — | — | — | — | |
| Zoetis Inc. | 15.96% | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2019 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × -5,356,995 ÷ 80,268,300 = -6.67%
4 Click competitor name to see calculations.
| Performance ratio | Description | The company |
|---|---|---|
| ROIC | A measure of the periodic, after tax, cash-on-cash yield earned in the business. | Allergan PLC ROIC improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019. |
Decomposition of ROIC
Allergan PLC, decomposition of ROIC
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
Operating Profit Margin (OPM)
Allergan PLC, OPM calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | (5,356,995) | (5,673,614) | (10,550,503) | (2,001,620) | (3,502,617) | |
| Add: Cash operating taxes2 | 897,358) | (398,902) | 1,237,785) | 294,697) | 398,183) | |
| Net operating profit before taxes (NOPBT) | (4,459,638) | (6,072,516) | (9,312,718) | (1,706,923) | (3,104,433) | |
| Net revenues | 16,088,900) | 15,787,400) | 15,940,700) | 14,570,600) | 15,071,000) | |
| Add: Increase (decrease) in deferred revenue | (9,500) | (1,800) | 22,200) | (2,500) | (8,100) | |
| Adjusted net revenues | 16,079,400) | 15,785,600) | 15,962,900) | 14,568,100) | 15,062,900) | |
| Profitability Ratio | ||||||
| OPM3 | -27.74% | -38.47% | -58.34% | -11.72% | -20.61% | |
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| AbbVie Inc. | 30.02% | — | — | — | — | |
| Amgen Inc. | 46.69% | — | — | — | — | |
| Bristol-Myers Squibb Co. | 21.63% | — | — | — | — | |
| Danaher Corp. | 18.74% | — | — | — | — | |
| Eli Lilly & Co. | 24.91% | — | — | — | — | |
| Gilead Sciences Inc. | 27.94% | — | — | — | — | |
| Johnson & Johnson | 21.00% | — | — | — | — | |
| Merck & Co. Inc. | 26.21% | — | — | — | — | |
| Pfizer Inc. | 35.42% | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 33.80% | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 17.61% | — | — | — | — | |
| Zoetis Inc. | 31.81% | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2019 Calculation
OPM = 100 × NOPBT ÷ Adjusted net revenues
= 100 × -4,459,638 ÷ 16,079,400 = -27.74%
4 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| OPM | The operating profit margin (OPM) is the ratio of pretax economic earnings, or NOPBT, to sales. | Allergan PLC OPM improved from 2017 to 2018 and from 2018 to 2019. |
Turnover of Capital (TO)
Allergan PLC, TO calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net revenues | 16,088,900) | 15,787,400) | 15,940,700) | 14,570,600) | 15,071,000) | |
| Add: Increase (decrease) in deferred revenue | (9,500) | (1,800) | 22,200) | (2,500) | (8,100) | |
| Adjusted net revenues | 16,079,400) | 15,785,600) | 15,962,900) | 14,568,100) | 15,062,900) | |
| Invested capital1 | 80,268,300) | 91,098,773) | 103,552,681) | 111,246,522) | 127,501,981) | |
| Efficiency Ratio | ||||||
| TO2 | 0.20 | 0.17 | 0.15 | 0.13 | 0.12 | |
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| AbbVie Inc. | 0.53 | — | — | — | — | |
| Amgen Inc. | 0.59 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 0.26 | — | — | — | — | |
| Danaher Corp. | 0.31 | — | — | — | — | |
| Eli Lilly & Co. | 1.04 | — | — | — | — | |
| Gilead Sciences Inc. | 0.70 | — | — | — | — | |
| Johnson & Johnson | 0.85 | — | — | — | — | |
| Merck & Co. Inc. | 0.87 | — | — | — | — | |
| Pfizer Inc. | 0.43 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 1.20 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 0.49 | — | — | — | — | |
| Zoetis Inc. | 0.64 | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 Invested capital. See details »
2 2019 Calculation
TO = Adjusted net revenues ÷ Invested capital
= 16,079,400 ÷ 80,268,300 = 0.20
3 Click competitor name to see calculations.
| Efficiency ratio | Description | The company |
|---|---|---|
| TO | The turnover of capital (TO) is the ratio of sales to invested capital. Capital turnover is a function of the efficiency of working capital management and of net fixed assets. | Allergan PLC TO improved from 2017 to 2018 and from 2018 to 2019. |
Effective Cash Tax Rate (CTR)
Allergan PLC, CTR calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | (5,356,995) | (5,673,614) | (10,550,503) | (2,001,620) | (3,502,617) | |
| Add: Cash operating taxes2 | 897,358) | (398,902) | 1,237,785) | 294,697) | 398,183) | |
| Net operating profit before taxes (NOPBT) | (4,459,638) | (6,072,516) | (9,312,718) | (1,706,923) | (3,104,433) | |
| Tax Rate | ||||||
| CTR3 | — | — | — | — | — | |
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| AbbVie Inc. | 7.42% | — | — | — | — | |
| Amgen Inc. | 17.97% | — | — | — | — | |
| Bristol-Myers Squibb Co. | 45.70% | — | — | — | — | |
| Danaher Corp. | 38.19% | — | — | — | — | |
| Eli Lilly & Co. | 11.34% | — | — | — | — | |
| Gilead Sciences Inc. | 34.29% | — | — | — | — | |
| Johnson & Johnson | 27.17% | — | — | — | — | |
| Merck & Co. Inc. | 19.04% | — | — | — | — | |
| Pfizer Inc. | 6.34% | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 16.36% | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 21.66% | — | — | — | — | |
| Zoetis Inc. | 21.17% | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2019 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 897,358 ÷ -4,459,638 = —
4 Click competitor name to see calculations.